Genetic and epigenetic characteristics of non-muscle invasive and muscle invasive bladder cancer in patients infected by human papillomavirus: literature review

Cover Page

Cite item

Full Text

Abstract

Infectious diseases and chronic inflammation are important risk factors for the development of malignant tumors in humans. One of the key infectious agents involved in human oncogenesis is the human papillomavirus (HPV). Non-muscle invasive bladder cancer is defined as a superficial neoplasia limited to the mucosa, aggravated by recurrence in 80 % of cases and progression in 30 % of cases. The development of this disease is associated with the influence of various carcinogenic agents, including HPV. Currently, a direct relationship has been revealed between the presence of viral DNA in the tumor tissue of the bladder and markers of proliferative activity, angiogenesis, and apoptosis factors. More and more researchers believe in the involvement of the virus in the development of recurrent forms of bladder cancer and the emergence of its invasive/poorly differentiated forms. Improving the diagnosis and postoperative monitoring of non-muscle invasive and muscle invasive bladder cancer is not possible without the improvement of minimally invasive molecular methods, which requires an understanding of the molecular mechanisms of HPV-associated carcinogenesis.

Therefore, this review focuses on the analysis of the molecular mechanisms of HPV effect on progression of non-muscle invasive and muscle invasive bladder cancer. The features of miRNA expression in patients with papillomavirus infection of high oncogenic risk types and non-muscle invasive or muscle invasive bladder cancer are considered in detail. In particular, the role of miR-34а, -218, -20a, -424, -200a, -205-5p, -944, -100, -99a, -202, -30a, -145-5p, -195 and -199a-5 is described in the development and progression of bladder cancer. The mechanisms of disruption in the functioning of key cell signaling pathways during HPV integration in patients with bladder cancer, including changes in gene copy number and methylation level, are also considered.

However, the number of HPV-positive tumor specimens that have been comprehensively analyzed using genome-wide studies in the literature remains small. Larger patient cohorts would be useful to further refine HPV-associated integration events and genomic changes, as well as to study clinical manifestations of the consequences of these alterations. Further research on the clinical implications of the observed genomic changes is needed to accurately stratify patients for targeted therapy, radiation and chemotherapy.

About the authors

A. A. Pulatova

National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: dr.pulatova05@gmail.com
ORCID iD: 0000-0003-1220-3297

63 14th Liniya, Rostov-on-Don 344037

Russian Federation

S. N. Dimitriadi

National Medical Research Center of Oncology, Ministry of Health of Russia

Email: dimitriadi@yandex.ru
ORCID iD: 0000-0002-2565-1518

63 14th Liniya, Rostov-on-Don 344037

Russian Federation

D. S. Kutilin

National Medical Research Center of Oncology, Ministry of Health of Russia

Email: k.denees@yandex.ru
ORCID iD: 0000-0002-8942-3733

63 14th Liniya, Rostov-on-Don 344037

Russian Federation

T. A. Zykova

National Medical Research Center of Oncology, Ministry of Health of Russia

Email: tatiana2904@yandex.ru
ORCID iD: 0000-0001-5345-4872

63 14th Liniya, Rostov-on-Don 344037

A. N. Shevchenko

National Medical Research Center of Oncology, Ministry of Health of Russia

Email: alexshew@mail.ru
ORCID iD: 0000-0002-9468-134X

63 14th Liniya, Rostov-on-Don 344037

Russian Federation

S. I. Goncharov

National Medical Research Center of Oncology, Ministry of Health of Russia

Email: sigon1954@mail.ru
ORCID iD: 0000-0001-6802-4736

63 14th Liniya, Rostov-on-Don 344037

Russian Federation

V. K. Khvan

National Medical Research Center of Oncology, Ministry of Health of Russia

Email: dfhwang@mail.ru
ORCID iD: 0000-0002-0036-7190

63 14th Liniya, Rostov-on-Don 344037

Russian Federation

References

  1. Kosova I.V., Loran O.B., Sinyakova L.A. et al. Immunohistochemical characteristics of bladder cancer in patients with viruspositive tumors. Onkourologiya = Cancer Urology 2018;14(2):142–54. (In Russ.). doi: 10.17650/1726-9776-2018-14-2-142-154
  2. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
  3. Pshikhachev A.M., Mikhaleva L.M., Gusniev M.A. et al. Сlinical and morphological features of non-muscle invasive bladder cancer: implications for treatment, prognosis and relapse of the disease (literature review). Onkourologiya = Cancer Urology 2021;17(1):134–41. (In Russ.). doi: 10.17650/1726-9776-2021-17-1-134-141
  4. Loran O.B., Sinyakova L.A., Gundorova L.V. et al. High oncogenic risk human papillomavirus and urinary bladder cancer. Urologiya = Urоlogy 2017;(3):60–6. (In Russ.).
  5. Musangile F.Y., Matsuzaki I., Okodo M. et al. Detection of HPV infection in urothelial carcinoma using RNAscope: Clinicopathological characterization. Cancer Med 2021;10(16):5534–44. doi: 10.1002/cam4.4091
  6. Nemtsova M.V., Kushlinskiy N.E. The molecular pathogenesis of bladder cancer. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine 2015;(41):79–88. (In Russ.). doi: 10.18786/2072-0505-2015-41-79-88
  7. Startsev V.Yu., Balashov A.E., Merzlyakov A.S. et al. Molecular determinants of recurrences of the human urothelial tumor. Onkourologiya = Cancer Urology 2021;17(3):130–9. (In Russ.). doi: 10.17650/1726-9776-2021-17-3-130-139
  8. Della Torre G., Pilotti S., De Palo G., Rilke F. Viral particles in cervical condylomatous lesions. Tumori 1978;64(5):549–53. doi: 10.1177/030089167806400513
  9. Boshart M., Gissmann L., Ikenberg H. et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3(5):1151–7. doi: 10.1002/j.1460-2075.1984.tb01944.x
  10. Smith N.J., Fenton T.R. The APOBEC3 genes and their role in cancer: insights from human papillomavirus. J Mol Endocrinol 2019;62(4):R269–87. doi: 10.1530/JME-19-0011
  11. Scarth J.A., Patterson M.R., Morgan E.L., Macdonald A. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J Gen Virol 2021;102(3):001540. doi: 10.1099/jgv.0.001540
  12. Parfenov M., Pedamallu C.S., Gehlenborg N. et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci USA 2014;111(43):15544–9. doi: 10.1073/pnas.1416074111
  13. Rusan M., Li Y.Y., Hammerman P.S. Genomic landscape of human papillomavirus-associated cancers. Clin Cancer Res 2015;21(9):2009–19. doi: 10.1158/1078-0432.CCR-14-1101
  14. He L., Yang B., Jian D. et al. Prognostic value of HPV E6 and APOBEC3B in upper urinary tract urothelial carcinoma. Dis Markers 2022;2022:2147494. doi: 10.1155/2022/2147494
  15. Sun J.X., Xu J.Z., Liu C.Q. et al. The association between human papillomavirus and bladder cancer: evidence from meta-analysis and two-sample mendelian randomization. J Med Virol 2022. doi: 10.1002/jmv.28208
  16. Muresu N., Di Lorenzo B., Saderi L. et al. Prevalence of human papilloma virus infection in bladder cancer: a systematic review. Diagnostics (Basel) 2022;12(7):1759. doi: 10.3390/diagnostics12071759
  17. Khatami A., Salavatiha Z., Razizadeh M.H. et al. Bladder cancer and human papillomavirus association: a systematic review and meta-analysis. Infect Agent Cancer 2022;17(1):3. doi: 10.1186/s13027-022-00415-5
  18. Collins K., Hwang M., Hamza A., Rao P. Prevalence of high-risk human papillomavirus in primary squamous cell carcinoma of urinary bladder. Pathol Res Pract 2020;216(9):153084. doi: 10.1016/j.prp.2020.153084
  19. Dimitriadi T.A., Burtsev D.V., Dzhenkova E.A., Kutilin D.S. Differential expression of microRNAs and their target genes in cervical intraepithelial neoplasias of varying severity. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2020;7(2): 47–61. (In Russ.). doi: 10.17650/2313-805X-2020-7-2-47-61
  20. Martinez I., Gardiner A.S., Board K.F. et al. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008;27(18):2575–82. doi: 10.1038/sj.onc.1210919
  21. Liu X. Up-regulation of miR-20a by HPV16 E6 exerts growthpromoting effects by targeting PDCD6 in cervical carcinoma cells. Biomed Pharmacother 2018;102:996–1002. doi: 10.1016/j.biopha.2018.03.154
  22. Cheng Y., Geng L., Zhao L. et al. Human papillomavirus E6-regulated microRNA-20b promotes invasion in cervical cancer by targeting tissue inhibitor of metalloproteinase 2. Mol Med Rep 2017;16:5464–70. doi: 10.3892/mmr.2017.7231
  23. Dimitriadi T.A., Burtsev D.V., Dzhenkova E.A., Kutilin D.S. Micro-RNA as markers of pre-cancer diseases progression in cervical cancer. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education 2020;(1):98–9. (In Russ.). doi: 10.17513/spno.29529
  24. Mandal P., Saha S.S., Sen S. et al. Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs. Cell Death Discov 2019;5:81. doi: 10.1038/s41420-019-0154-x
  25. Qian K., Pietila T., Ronty M. et al. Identification and validation of human papillomavirus encoded microRNAs. PLoS One 2013;8:e70202. doi: 10.1371/journal.pone.0070202
  26. Tornesello M.L., Faraonio R., Buonaguro L. et al. The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer. Front Oncol 2020;10:150. doi: 10.3389/fonc.2020.00150
  27. Borkowska E.M., Konecki T., Pietrusiński M. et al. MicroRNAs which can prognosticate aggressiveness of bladder cancer. Cancers (Basel) 2019;11(10):1551. doi: 10.3390/cancers11101551
  28. Alter B.P., Giri N., Savage S.A. et al. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus. Int J Cancer 2013;133(6):1513–5. doi: 10.1002/ijc.28157
  29. Moisoiu T., Dragomir M.P., Iancu S.D. et al. Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer. Mol Med 2022;28(1):39. doi: 10.1186/s10020-022-00462-z
  30. Campbell J.D., Yau C., Bowlby R. et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep 2018;23(1):194–212.e6. doi: 10.1016/j.celrep.2018.03.063
  31. Ojesina A.I., Lichtenstein L., Freeman S.S. et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014;506(7488):371–5. doi: 10.1038/nature12881
  32. McConnell B.B., Ghaleb A.M., Nandan M.O., Yang V.W. The diverse functions of Kruppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays 2007;29:549–57. doi: 10.1002/bies.20581
  33. Graziano V., De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta 2011;1816(1):57–66. doi: 10.1016/j.bbcan.2011.04.002
  34. Akagi K., Li J., Broutian T.R. et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 2014;24(2):185–99. doi: 10.1101/gr.164806.113
  35. Tsandekova M.R., Porkhanova N.V., Kit O.I., Kutilin D.S. Minimally invasive molecular diagnostics of high-grade and low-grade serous adenocarcinoma of the ovarian. Oncogynecologiya = Oncogynecology 2021;(4(40)):35–49. (In Russ.).
  36. Shin H.J., Joo J., Yoon J.H. et al. Physical status of human papillomavirus integration in cervical cancer is associated with treatment outcome of the patients treated with radiotherapy. PLoS One 2014;9(1):e78995. doi: 10.1371/journal.pone.0078995
  37. Wilting S.M., Smeets S.J., Snijders P.J. et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics 2009;2:32. doi: 10.1186/1755-8794-2-32
  38. Lajer C.B., Garnaes E., Friis-Hansen L. et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 2012;106(9):1526–34. doi: 10.1038/bjc.2012.109
  39. Mirghani H., Amen F., Blanchard P. et al. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 2015;136(7):1494–503: doi: 10.1002/ijc.28847

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.